Britain and America have signed a key bilateral deal that will maintain zero tariffs on British medicine products going into the US market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has agreed to raise funding on medicines through the public health system. This move ensures that tariffs on these crucial exports will stay at nothing for a duration of three years.
This agreement follows recent statements to significantly raise tariffs on patented drug products, with potential rates discussed reaching 100%.
"This agreement between the Britain bolsters the international landscape for new treatments and introduces much-needed equity to U.S.–U.K. pharmaceutical trade," a release declared.
Trade Impact
Medicines are one of the UK's biggest exports to the US, which is clearly the biggest buyer for leading UK drugmakers.
Statistics indicate that in the 12 months prior to September, the UK sold medicines valued at billions to the US. This value represented 17.4% of total UK exports in that span.
"This deal secures employment, increases funding and facilitates the UK to emerge as a international leader for biotech and pharma," the Business and Trade Secretary remarked.
Key British Pledges
The pact entails several key changes from the British government:
- Price Threshold Increase: The UK will raise the cost ceiling at which it considers new treatments to be too expensive by 25%.
- Boosted Medicine Funding: There is a goal to increase total NHS spending on medicines from 0.3% of GDP to 0.6 percent over the coming ten years.
- Refund Ceiling: The sum drug companies must pay back to the NHS to prevent overspending will be limited at fifteen percent. In the past, refunds were more than twenty percent.
Broader Context
The pact takes place against a ongoing tension between the drug companies and the UK government over drug pricing and approval rates.
This friction were exacerbated by claims that American consumers were paying a premium for the equivalent treatments than people in the other developed nations.
In recent months, several significant drug company projects in the UK have been delayed or abandoned, while substantial expansions have been announced toward US facilities.
One official stated that the NHS had to invest a greater share on treatments, noting that its spending on drugs had shrunk as a share of its overall budget over the past decade.
